Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification

Logo poskytovatele

Varování

Publikace nespadá pod Filozofickou fakultu, ale pod Středoevropský technologický institut. Oficiální stránka publikace je na webu muni.cz.
Autoři

SUTTON LA. HADZIDIMITRIOU A. BALIAKAS P. AGATHANGELIDIS A. LANGERAK A. STILGENBAUER S. POSPÍŠILOVÁ Šárka DAVIS Z. FORCONI F. DAVI F. GHIA P. ROSENQUIST R. STAMATOPOULOS K.

Rok publikování 2017
Druh Článek v odborném periodiku
Časopis / Zdroj Haematologica/the hematology journal
Fakulta / Pracoviště MU

Středoevropský technologický institut

Citace
Doi http://dx.doi.org/10.3324/haematol.2017.165605
Obor Onkologie a hematologie
Klíčová slova CLL; immunoglobulin; B-cell
Popis While triggering through the B-cell receptor (BcR) facilitates B-cell development and maintenance, it also carries intertwined risks for the emergence of lymphoid malignancies, since malignant B cells can exploit BcR signaling pathways in order to initiate and fuel clonal expansion. Indeed, substantial research into chronic lymphocytic leukemia (CLL), largely based on immunogenetic data, supports the notion that the clonotypic BcR immunoglobulin (IG) engages in the recognition of and selection by putative (auto)antigen.1 This highlights the critical role of the BcR IG in the pathophysiology of CLL and implies that disease development is functionally driven and dynamic, rather than being a simple stochastic process. From a clinical perspective, the remarkable therapeutic efficacy of novel drugs such as ibrutinib and idelalisib which target effectors of the BcR signaling pathway (BTK and PI3K™, respectively), further vouch for this idea, and herald a major paradigm shift which may ultimately lead to changes in the natural history of the disease
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.